Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients

Song, Peng; Yang, Dongliang; Wang, Hanping; Cui, Xiaoxia; Si, Xiaoyan; Zhang, Xiaolin; Zhang, Li

doi:10.1111/1759-7714.13447

Cited by 19 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also know now that even targeted cancer therapies impact tumor growth by affecting not just the tumor cells but also the immune system (Deng et al, 2018;Goel et al, 2017). The same is true for the cancer therapies aimed at the immune system that work very differently depending on the genotype of the tumor (Song et al, 2020).…”

Section: Reconciling Synthetic Biology With Ecology and Evolutionmentioning

confidence: 99%

Functional biology in its natural context: A search for emergent simplicity

Bergelson

Kreitman

Petrov

et al. 2021

eLife

View full text Add to dashboard Cite

show abstract

Section: Reconciling Synthetic Biology With Ecology and Evolutionmentioning

confidence: 99%

Functional biology in its natural context: A search for emergent simplicity

Bergelson

Kreitman

Petrov

et al. 2021

eLife

View full text Add to dashboard Cite

show abstract

“…In urothelial cancer, PD-(L)1 inhibitors are currently mostly used as second-line treatment for patients with metastatic disease who progressed on platinum-based chemotherapy [ 85 ]. Recent trials investigating the efficacy of checkpoint inhibition in the first-line setting showed no survival benefit for checkpoint inhibitors over chemotherapy in the overall population [ 86 , 87 ].…”

Section: Checkpoint Inhibitor Therapy In Brca-inactivated Tumorsmentioning

confidence: 99%

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity

Wilpe

Tolmeijer

Koornstra

et al. 2021

Cancers

View full text Add to dashboard Cite

Homologous recombination repair deficiency (HRD) can be observed in virtually all cancer types. Although HRD sensitizes tumors to DNA-damaging chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors, all patients ultimately develop resistance to these therapies. Therefore, it is necessary to identify therapeutic regimens with a more durable efficacy. HRD tumors have been suggested to be more immunogenic and, therefore, more susceptible to treatment with checkpoint inhibitors. In this review, we describe how HRD might mechanistically affect antitumor immunity and summarize the available translational evidence for an association between HRD and antitumor immunity across multiple tumor types. In addition, we give an overview of all available clinical data on the efficacy of checkpoint inhibitors in HRD tumors and describe the evidence for using treatment strategies that combine checkpoint inhibitors with PARP inhibitors.

show abstract

“…Lung Cancer is one of the most common neoplastic disease and a leading cause of cancer mortality worldwide, approximately 18.4% of all deaths [56][57][58][59]. It has been increasing in certain population such as nonsmokers and female in developing country, while declining in males in most developed countries [56,57].…”

Section: Lung Cancersmentioning

confidence: 99%

“…It has been increasing in certain population such as nonsmokers and female in developing country, while declining in males in most developed countries [56,57]. The most common subtype is non-small cell lung cancer (NSCLC), accounting about 85% [58][59][60]. The majority NSCLC patient are diagnosed at advanced stage, about 50% of them displaying clinically at stage IV and poor prognosis of a five-year survival rate between less than 20% [56][57][58][59][60].…”

Section: Lung Cancersmentioning

confidence: 99%

The Role of BRAF Gene in Cancer: Literature Review and Future Directions

Hsieh¹

2020

J. Can. Res. Updates

View full text Add to dashboard Cite

The BRAF gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays an important role in regulating the MAP kinase signaling pathway, which is involved in cellular development, differentiation, division, proliferation, secretion, inflammatory responses and apoptosis in mammalian cells.Since 2002, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent, and it is found to be recurrent in many cancer types. It is frequently identified cancer-causing mutation in melanoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia, non-Hodgkin lymphoma, glioneuronal tumors, hepatocellular carcinoma, adenocarcinoma of lung, ovarian cancer, and also others malignancies and some cancer metastasis.In the early 1990s, some researchers began studying MAP kinase signaling pathway involved in controlling cell growth and its role in cancer, and it helped identify targets for new classes of cancer therapy. Later BRAF mutation was found in over 50% of melanomas. The overactive BRAF protein expression looked like an attractive drug target. Elucidating the detailed molecular structure of the mutant protein helped pharmaceutical companies developed selective inhibitors of mutated BRAF, including Vemurafenib and Dabrafenib, which have been approved to treat melanoma by the Food and Drug Administration (FDA).In addition, there is a growing number of targeted agents that are being evaluated to treat various BRAF-mutant advanced cancer (especially melanoma, lung, thyroid and colorectal cancer), including other RAF kinase inhibitors and/or MEK inhibitors.The standard therapy of inhibition of BRAF mutation in advanced melanoma and/or others malignancies, improved clinical benefit compared to chemotherapy. In the meantime, intrinsic and acquired resistances are still key challenges by using these drugs. The future research is heading to understand the mechanisms of the resistance, therefore it will help us to understand diseases biology and continuously bringing new therapeutic strategies for melanoma and/or others malignancies, including other drugs combination and next-generation of BRAF inhibitors.

show abstract

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients

Cited by 19 publications

References 20 publications

Functional biology in its natural context: A search for emergent simplicity

Functional biology in its natural context: A search for emergent simplicity

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity

The Role of BRAF Gene in Cancer: Literature Review and Future Directions

Contact Info

Product

Resources

About